Accurius Therapeutics

Accurius Therapeutics is a private, pre-clinical stage biotech focused on pioneering a novel oncolytic immunotherapy platform for cancer. The company is developing a targeted treatment for metastatic Non-Small Cell Lung Cancer (NSCLC), a major area of unmet medical need. By integrating advanced viral technology with proprietary delivery systems, Accurius seeks to enhance the potency and specificity of oncolytic virotherapy. The company is led by a team of experienced researchers and commercial leaders, positioning it to advance its lead candidate through development.

Integrated platform combining engineered oncolytic viruses for tumor cell lysis and immune activation with a proprietary drug delivery system designed to enhance systemic targeting, delivery, and potency in solid tumors.

The oncolytic virotherapy field is competitive, with several clinical-stage companies (e.g., Replimune, Turnstone Biologics) and approved products (Amgen's T-VEC). Accurius must differentiate through superior delivery/targeting technology and demonstrate clinical advantage in a crowded oncology immunotherapy market dominated by checkpoint inhibitors.